US FDA Could Be Facing Bolus Of Pandemic-Related Applications
Executive Summary
Acting CDER Director Cavazzoni says it is ‘a very active time’ as many clinical trials for COVID-19-related products are expected to read out soon.
You may also be interested in...
Cavazzoni Helms US FDA Drug Center With OTC Monograph Reform Starting, Novel Switches Next
Patrizia Cavazzoni, who likely represents a somewhat different leadership style for CDER, distinguished herself while leading the center temporarily during the COVID-19 pandemic.
Woodcock Era At CDER Ends: Cavazzoni Becomes Permanent Director Of US FDA’s Drug Center
Patrizia Cavazzoni, who likely represents a somewhat different leadership style for CDER, distinguished herself while leading the center temporarily during the COVID-19 pandemic.
The COVID Boom: CBER Receives More INDs in One Quarter Than The Previous 30 Combined
Bubble was short-lived, but still could create workload problems for the US FDA as it navigates the end of the coronavirus pandemic.